Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nu Holdings
NU
5
Liberty Latin America-A
LILA
HK Stock MarketDetailed Quotes
09969 INNOCARE
- 10.240
- -0.280-2.66%
Trading Apr 25 13:51 CST
18.03BMarket Cap-37.93P/E (TTM)
10.760High9.980Low7.75MVolume10.660Open10.520Pre Close79.49MTurnover0.52%Turnover RatioLossP/E (Static)1.76BShares10.96052wk High2.48P/B15.30BFloat Cap4.22052wk Low--Dividend TTM1.49BShs Float32.050Historical High--Dividend LFY7.41%Amplitude4.030Historical Low10.250Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
About INNOCARE Company
The company is a commercialized biomedical high-tech company. It was co-founded in 2015 by Dr. Cui Jisong, who has rich experience in new drug development and enterprise management, and Academician Shi Yigong, a world-famous structural biologist. We develop innovative drugs for patients with malignant tumors and autoimmune diseases, so that innovative results can benefit more patients. The company is a high-tech innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D, production and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and develops first-of-its-kind or best-in-class drugs with breakthrough potential in the global market. Main products: obutinib, ICP-B04, ICP-248, ICP-B02, ICP-490, ICP-B05, ICP-332, ICP-488, IL-17 small molecule,, ICP-B794, etc. ICP-723 ICP-189
Company Profile
Symbol09969
Company NameINNOCARE
ISINKYG4783B1032
Listing DateMar 23, 2020
Issue Price8.95
Shares Offered250.32M share(s)
FoundedNov 3, 2015
Registered AddressCayman Islands
Chairmanjisong cui
Secretaryxiepeishan li
Audit InstitutionErnst & Young, Ernst & Young Huaming
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeOgier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees1109
MarketHong Kong motherboard
Phone86-010-66609913
Fax86-010-60702992
Emailinfo@innocarepharma.com
BusinessNuochengjianhua is an innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and develops best-in-class or first-of-its-kind drugs with breakthrough potential in the global market.
Company Executives
- Name
- Position
- Salary
- jisong cui
- Presidencies, CEO, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Authorized Representative
- --
- renbin zhao
- Executive Director
- --
- yigong shi
- Non-executive Directors
- --
- kunliang guan
- Independent Non-Executive Director
- --
- ronggang xie
- Non-executive Directors, Audit Committee Members
- --
- dandan dong
- Independent Non-Executive Director, Nomination Committee Members, Remuneration Committee Members, Audit Committee Members
- --
- lan hu
- Independent Non-Executive Director, Remuneration Committee Chairman, Chairman of the Audit Committee, Nomination Committee Members
- --
- xin fu
- Chief Financial Officer
- --
- xiangyang zhang
- Chief Medical Officer
- --
- xiangyang chen
- Chief Technology Officer
- --
- xiepeishan li
- Authorized Representative, Company Secretary
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs